<SEC-DOCUMENT>0001171520-22-000272.txt : 20220502
<SEC-HEADER>0001171520-22-000272.hdr.sgml : 20220502
<ACCEPTANCE-DATETIME>20220502172931
ACCESSION NUMBER:		0001171520-22-000272
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20220502
DATE AS OF CHANGE:		20220502

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		22883456

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SINGER JULIAN D.
		CENTRAL INDEX KEY:			0001628706

	FILING VALUES:
		FORM TYPE:		DFAN14A

	MAIL ADDRESS:	
		STREET 1:		2200 FLETCHER AVENUE
		STREET 2:		SUITE 501
		CITY:			FORT LEE
		STATE:			NJ
		ZIP:			07024
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>eps10201.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 13.5pt Times New Roman,serif; margin: 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 13.5pt Times New Roman,serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 8pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman,serif; margin: 0; text-align: center"><B>SCHEDULE 14A </B></P>

<P STYLE="font: 6pt Times New Roman,serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a) of the </B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>(Amendment No. )</B></P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">Filed by the Registrant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: MS Gothic">&#9744;</FONT></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">Filed by a Party other than the Registrant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: MS Gothic">&#9745;</FONT></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">Check the appropriate box:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD><TD>Preliminary Proxy Statement</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD><TD>Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD><TD>Definitive Proxy Statement</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD><TD>Definitive Additional Materials</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9745;</FONT></TD><TD>Soliciting Material Pursuant to &sect;240.14a-12</TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>CATALYST BIOSCIENCES, INC.</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>(Name of Registrant as Specified in Its Charter)</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>JDS1, LLC</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>CCUR HOLDINGS, INC.</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>CIDM II, LLC</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>JULIAN D. SINGER</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>DAVID S. OROS</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>SHELLY C. LOMBARD</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>MATTHEW STECKER</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>IGOR VOLSHTEYN</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement, if Other Than
the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0">Payment of Filing Fee (Check the appropriate box):</P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 12pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-family: Times New Roman,serif"><FONT STYLE="font-family: MS Gothic">&#9745;</FONT></TD>
    <TD STYLE="width: 96%; font-family: Times New Roman,serif; text-align: justify">No fee required</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman,serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif">Fee paid previously with preliminary materials</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman,serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">JDS1, LLC, a Delaware limited liability company (&ldquo;JDS1&rdquo;),
CCUR Holdings, Inc., a Delaware corporation (&ldquo;<U>CCUR</U>&rdquo;), CIDM II, LLC, a Delaware limited liability company (&ldquo;<U>CIDM
II</U>&rdquo;), Julian D. Singer, David S. Oros, Shelly C. Lombard, Matthew Stecker, and Igor Volshteyn (collectively, the &ldquo;<U>JDS1
Group</U>&rdquo;), have filed a preliminary proxy statement and accompanying GOLD proxy card with the U.S. Securities and Exchange Commission
(&ldquo;<U>SEC</U>&rdquo;) to be used solicit proxies from the stockholders of Catalyst Biosciences, Inc., a Delaware Corporation (the
&ldquo;<U>Company</U>&rdquo;), in connection with the Company&rsquo;s 2022 Annual Meeting of Stockholders, any special meeting held in
lieu thereof, and at any and all adjournments or postponements thereof (the &ldquo;<U>2022 Annual Meeting</U>&rdquo;).</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify"><B>Schedule 13D Amendment No. 11 Filed on May 2, 2022</B></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">On May 2, 2022, the JDS1 Group filed Amendment No.
11 to its Schedule 13D with respect to the Company (the &ldquo;<U>Schedule 13D/A</U>&rdquo;). The following disclosure was included in
Item 4 of the Schedule 13D/A and is being included in this Schedule 14A because such disclosure may be deemed&nbsp;to be solicitation
material in connection with the JDS1 Group&rsquo;s plans to solicit proxies from the Company&rsquo;s stockholders for use at the 2022
Annual Meeting:</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0.5in 12pt; text-align: justify; background-color: white">&ldquo;On April 28, 2022,
JDS1 and the other reporting persons named herein (collectively, the &ldquo;<U>JDS1 Group</U>&rdquo;) filed a preliminary proxy statement
(the &ldquo;<U>JDS1 Preliminary Proxy Statement</U>&rdquo;) and accompanying GOLD proxy card with the SEC in connection with the JDS1
Group&rsquo;s plans to solicit proxies for the Issuer&rsquo;s 2022 Annual Meeting of Stockholders, any special meeting held in lieu thereof,
and at any and all adjournments or postponements thereof (the &ldquo;<U>2022 Annual Meeting</U>&rdquo;). At the 2022 Annual Meeting, the
JDS1 Group is seeking to have stockholders elect the three nominees, Shelly C. Lombard, Matthew Stecker, and Igor Volshteyn, JDS1 has
nominated for election to the Issuer&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;) and approve a non-binding stockholder
proposal requesting that the Board take the necessary steps to declassify the Board (in a manner that does not affect the unexpired terms
of the previously elected directors) and to require that all directors stand for election annually, with such declassification of the
Board done in the most expeditious manner available under the Delaware General Corporation Law. JDS1 believes that its nominees are highly
qualified, extremely capable, ready to serve the best interests of all the Issuer&rsquo;s stockholders and committed to fully exploring
all opportunities to stop and reverse the precipitous decline in the Issuer&rsquo;s stock price. As of the close of business on April
29, 2022, the Common Stock closed at a price of $0.48 per share, which represents an approximately 90.5% decline from the Common Stock&rsquo;s
closing price of $5.04 per share a year ago on April 30, 2021. In addition, the Common Stock has spent more than thirty (30) consecutive
trading days below $1.00, the latter condition subjecting the Issuer to the risk of being delisted by the Nasdaq Stock Market.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0.5in 12pt; text-align: justify; background-color: white">In filing the JDS1
Preliminary Proxy Statement with the SEC, the JDS1 Group believed that the Issuer had fixed the record date for the 2022 Annual
Meeting as April 19, 2022 and had scheduled the 2022 Annual Meeting for June 8, 2022. At the time that the JDS1 Preliminary Proxy
Statement was filed with the SEC, it was the understanding of the JDS1 Group that the Issuer had previously notified Broadridge
Financial Solutions, Inc. (&ldquo;<U>Broadridge</U>&rdquo;) of such record and annual meeting dates. In addition, on April 20, 2022,
JDS1 delivered to the Issuer a record date supplement to its previously delivered advance notice of nominations and other proposed
business, as required by the Issuer&rsquo;s Amended and Restated Bylaws, which clearly referenced that information was being
provided to the Issuer in connection with JDS1&rsquo;s understanding that the record date for the 2022 Annual Meeting was set at
April 19, 2022. Upon receipt of such record date supplement, none of the Issuer, the Issuer&rsquo;s Chief Executive Officer, the
Issuer&rsquo;s Interim Chief Financial Officer, the Board&rsquo;s Nominating and Governance Committee Chair, or the Issuer&rsquo;s
counsel, each of whom was emailed a copy of the record date supplement, challenged JDS1&rsquo;s understanding that the record date for
the 2022 Annual Meeting was April 19, 2022. Further, as previously disclosed, on March 15, 2022, JDS1 submitted to the Issuer a
stockholder inspection demand seeking various stock ownership and other records (the &ldquo;<U>JDS1 Inspection Demand</U>&rdquo;),
including as of the record date for the 2022 Annual Meeting. Further, as also previously disclosed, on April 20, 2022, JDS1 filed
suit against the Issuer in Delaware Chancery Court to enforce the JDS1 Inspection Demand. In the documents submitted to the Delaware
Chancery Court in connection with that litigation, such as the Complaint and a related Motion for Expedited Proceedings, reference
is made to JDS1&rsquo;s understanding that the 2022 Annual Meeting was scheduled for June 8, 2022 and the associated record date was
set as April 19, 2022. At no point, prior to the filing of the JDS1 Preliminary Proxy Statement, did the Issuer or its counsel
question JDS1&rsquo;s understanding that the date of the 2022 Annual Meeting was scheduled for June 8, 2022 and/or that the
associated record date was fixed as April 19, 2022. Subsequent to filing the JDS1 Preliminary Proxy Statement with the SEC,
JDS1&rsquo;s counsel received an emailed letter from the Issuer&rsquo;s counsel in connection with the JDS1 Inspection Demand and
the related litigation. In that letter, the Issuer&rsquo;s counsel represented that the date of the 2022 Annual Meeting and the
associated record date had not been set<I>.</I> In response to an email from JDS1&rsquo;s counsel indicating its understanding that
the Issuer had previously notified Broadridge that the 2022 Annual Meeting was scheduled for June 8, 2022 and/or that the associated
record date was fixed as April 19, 2022, the Issuer&rsquo;s counsel asserted that the Issuer had never provided any definitive
meeting or record dates to Broadridge in connection with the 2022 Annual Meeting and represented again that the Issuer had never set
a record or meeting date for the 2022 Annual Meeting.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0.5in 12pt; text-align: justify; background-color: white">Taking into consideration
that the Issuer had produced certain records to JDS1 on April 21, 20022 and April 25, 2022 and, by letter dated April 28, 2022, the Issuer
had (i) represented it had produced all documents in its possession, custody, or control responsive to JDS1&rsquo;s requests as of that
date, (ii) committed to promptly produce certain additional documents to JDS1, including, but not limited to, an updated stockholder list
as of the record date for the 2022 Annual Meeting, and (iii) represented that the date of the 2022 Annual Meeting and the associated record
date had not been set, by a stipulation dated May 2, 2022, JDS1 and the Issuer agreed to remove from the Delaware Chancery Court&rsquo;s
calendar its hearing on JDS1&rsquo;s Motion for Expedited Proceedings that had been scheduled for May 6, 2022 and to vacate the related
schedule for submissions related to that Motion for Expedited Proceedings that the Court had imposed on the Issuer and JDS1.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0.5in 12pt; text-align: justify; background-color: white">Except as set forth in
this Schedule 13D or such as would occur upon or in connection with completion of, or following, any of the actions discussed in this
Schedule 13D, no Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in
subparagraphs (a) - (j) of Item 4 of Schedule 13D. The Reporting Persons intend to review their investment in the Issuer on a continuing
basis. Depending on various factors including, without limitation, the Issuer&rsquo;s financial position and strategic direction, actions
taken by the Board, the price levels of the Shares, other investment opportunities available to the Reporting Persons, conditions in the
securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect
to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications with management and/or
the Board, engaging in communications with one or more stockholders of the Issuer and others about the Issuer and the Reporting Persons&rsquo;
investment, making suggestions and/or proposals concerning the Issuer&rsquo;s capitalization, ownership structure, operations, prospects,
business and financial strategies, strategic transactions, assets and liabilities, business and financing alternatives, the structure
and composition of the Board, and such other matters as the Reporting Persons may deem relevant to their investment in the Issuer, selling
some or all of their Shares in the open market or otherwise, engaging in short selling of or any hedging or similar transaction with respect
to the Shares, acquiring additional Shares and/or other equity, debt, notes, other securities, or derivative or other instruments that
are based upon or relate to the value of securities of the Issuer, or changing their intention with respect to any and all matters referred
to in Item 4.&rdquo;</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 8pt"><B>Important Additional Information and Certain Information Concerning the
Participants</B></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">The JDS1 Group has filed a preliminary proxy statement
and accompanying GOLD proxy card with the SEC to be used to solicit proxies from the Company&rsquo;s stockholders in connection with the
2022 Annual Meeting to have stockholders elect three director nominees to the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;)
and approve a non-binding proposal requesting that the Board take the necessary steps to declassify the Board (in a manner that does not
affect the unexpired terms of the previously elected directors) so that all directors are elected on an annual basis, with such declassification
of the Board done in the most expeditious manner available under the Delaware General Corporation Law.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">THE JDS1 GROUP STRONGLY ADVISES ALL STOCKHOLDERS OF
THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT&nbsp;HTTPS://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN
THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD
BE DIRECTED TO THE PARTICIPANTS&rsquo; PROXY SOLICITOR.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">The participants in the proxy solicitation are anticipated
to be JDS1, LLC, a Delaware limited liability company, CCUR Holdings, Inc., a Delaware corporation, CIDM II, LLC, a Delaware limited liability
company, Julian D. Singer, David S. Oros, Shelly C. Lombard, Matthew Stecker, and Igor Volshteyn.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">As of the date hereof, JDS1, LLC beneficially owns
directly 780,432 shares of Common Stock, par value $0.001 per share, of the Company (the &ldquo;<U>Common Stock</U>&rdquo;), including
500 shares of Common Stock held in record name. As of the date hereof, CCUR Holdings, Inc. beneficially owns directly 532,100 shares of
Common Stock. JDS1, LLC, as an affiliate of CCUR Holdings, Inc., may also be deemed to be the beneficial owner of the 532,100 shares of
Common Stock held by CCUR Holdings, Inc. As of the date hereof, CIDM II, LLC does not directly own any shares of Common Stock, but, as
the asset manager to CCUR Holdings, Inc., may be deemed the beneficial owner of the 532,100 shares of Common Stock beneficially owned
by CCUR Holdings, Inc. As of the date hereof, Mr. Singer does not directly own any shares of Common Stock, but may be deemed to have beneficial
ownership of the Common Stock as a result of being the managing member of each of JDS1 and CIDM II, LLC and an affiliate of CCUR Holdings,
Inc. Accordingly, Mr. Singer may be deemed to beneficially own (i) the 780,432 shares of Common Stock beneficially owned directly by JDS1,
LLC, and (ii) the 532,100 shares of Common Stock beneficially owned directly by CCUR Holdings, Inc. As of the date hereof, Mr. Oros directly
beneficially owns 338,600 shares of Common Stock. As of the date hereof, none of Ms. Lombard and Messrs. Stecker and Volshteyn beneficially
owned any shares of Common Stock.</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
